DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin icodec

First Posted Date: 2020-10-22

Last Posted Date: 2024-07-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 25

Registration Number: NCT04597697

Locations: 🇸🇰
Summit Clinical Research s.r.o., Bratislava, Slovakia
🇨🇿
Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia

Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1

Interventions: Drug: Faster aspart
Drug: Insulin aspart
Drug: Insulin degludec

First Posted Date: 2020-10-19

Last Posted Date: 2025-03-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 331

Registration Number: NCT04588259

Locations: 🇨🇳
Anhui Provincial Hospital-Endocrinology, Hefei, Anhui, China
🇨🇳
Beijing Chao-yang Hospital, Capital Medical University-Endocrinology, Beijing, Beijing, China
🇨🇳
Chinese People's Liberation Army General Hospital-Endocrinology, Beijing, Beijing, China

and more 33 locations

Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities

Completed

Conditions: Haemophilia A

Interventions: Drug: Turoctocog alfa

First Posted Date: 2020-10-14

Last Posted Date: 2023-11-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT04584892

Locations: 🇮🇹
Novo Nordisk Investigational Site, Vicenza, Italy

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Icodec

First Posted Date: 2020-10-09

Last Posted Date: 2023-09-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 46

Registration Number: NCT04582435

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin icodec

First Posted Date: 2020-10-09

Last Posted Date: 2023-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 25

Registration Number: NCT04582448

Locations: 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany

A Study of FT-7051 in Men With MCRPC

Phase 1

Terminated

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: FT-7051

First Posted Date: 2020-10-05

Last Posted Date: 2023-08-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 25

Registration Number: NCT04575766

Locations: 🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸
University of Colorado Health, Aurora, Colorado, United States

and more 5 locations

A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: NNC0268-0965
Drug: Insulin glargine
Drug: Placebo (insulin glargine)
Drug: Placebo (NNC0268-0965)

First Posted Date: 2020-10-05

Last Posted Date: 2024-01-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 86

Registration Number: NCT04575181

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇩🇪
Profil GmbH & Co. KG, Mainz, Germany

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®

Conditions: Haemophilia A

Interventions: Drug: Turoctocog alfa pegol (N8-GP)

First Posted Date: 2020-10-05

Last Posted Date: 2025-05-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 60

Registration Number: NCT04574076

Locations: 🇪🇸
Hospital Regional Universitario de Málaga, Málaga, Spain
🇦🇹
AKH - Klin. Abt. f. Haematologie u. Haemostaseologie, Wien, Austria
🇭🇷
KBC Zagreb, Rebro, Hemofilija centar, Zagreb, Croatia

and more 21 locations

Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Ozempic®
Drug: Active Comparator
Drug: Rybelsus®

First Posted Date: 2020-10-01

Last Posted Date: 2024-01-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 600000

Registration Number: NCT04572165

Locations: 🇩🇰
Novo Nordisk Investigational Site, Odense, Denmark

A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Healthy Volunteers

Interventions: Drug: NNC0363-0845
Drug: Placebo (NNC0363-0845)
Drug: Insulin degludec

First Posted Date: 2020-09-30

Last Posted Date: 2023-06-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 68

Registration Number: NCT04569994

Locations: 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy